{"filing":{"accession_number":"0001140361-26-030491","cik":"0001723128","ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ef20079129_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723128/000114036126030491/ef20079129_8k.htm"},"events":[{"id":22385,"run_id":20248,"accession_number":"0001140361-26-030491","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the results of a special meeting of stockholders held on July 31, 2026, where shareholders voted on and approved three proposals: (1) the Transaction Proposal to approve a Membership Interest Purchase Agreement for Amneal to acquire 100% of Kashiv BioSciences, LLC; (2) the Stock Issuance Proposal to approve issuance of 28,942,108 shares of Common Stock to the sellers; and (3) an Adjournment Proposal (not submitted). The voting results show strong approval with 138,265,079 votes for the Transaction Proposal and 286,714,072 votes for the Stock Issuance Proposal. This is a material acquisition transaction requiring shareholder approval, making the vote results material to investors.","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22309,"accession_number":"0001140361-26-030491","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of a special meeting of stockholders held on July 31, 2026, where shareholders voted on and approved three proposals: (1) the Transaction Proposal to approve a Membership Interest Purchase Agreement for Amneal to acquire 100% of Kashiv BioSciences, LLC; (2) the Stock Issuance Proposal to approve issuance of 28,942,108 shares of Common Stock to the sellers; and (3) an Adjournment Proposal (not submitted). The voting results show strong approval with 138,265,079 votes for the Transaction Proposal and 286,714,072 votes for the Stock Issuance Proposal. This is a material acquisition transaction requiring shareholder approval, making the vote results material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:11:18.145186+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22309,"accession_number":"0001140361-26-030491","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of a special meeting of stockholders held on July 31, 2026, where shareholders voted on and approved three proposals: (1) the Transaction Proposal to approve a Membership Interest Purchase Agreement for Amneal to acquire 100% of Kashiv BioSciences, LLC; (2) the Stock Issuance Proposal to approve issuance of 28,942,108 shares of Common Stock to the sellers; and (3) an Adjournment Proposal (not submitted). The voting results show strong approval with 138,265,079 votes for the Transaction Proposal and 286,714,072 votes for the Stock Issuance Proposal. This is a material acquisition transaction requiring shareholder approval, making the vote results material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:11:18.145186+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-07-31"}]}